Ahmad Ehtasham, Lim Soo, Lamptey Roberta, Webb David R, Davies Melanie J
Diabetes Research Centre, University of Leicester and the Leicester NIHR Biomedical Research Centre, Leicester General Hospital, Leicester, UK.
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Lancet. 2022 Nov 19;400(10365):1803-1820. doi: 10.1016/S0140-6736(22)01655-5. Epub 2022 Nov 1.
Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes worldwide. The number affected is increasing rapidly with alarming trends in children and young adults (up to age 40 years). Early detection and proactive management are crucial for prevention and mitigation of microvascular and macrovascular complications and mortality burden. Access to novel therapies improves person-centred outcomes beyond glycaemic control. Precision medicine, including multiomics and pharmacogenomics, hold promise to enhance understanding of disease heterogeneity, leading to targeted therapies. Technology might improve outcomes, but its potential is yet to be realised. Despite advances, substantial barriers to changing the course of the epidemic remain. This Seminar offers a clinically focused review of the recent developments in type 2 diabetes care including controversies and future directions.
2型糖尿病占全球约5.37亿糖尿病病例的近90%。受影响的人数正在迅速增加，儿童和年轻人（40岁以下）中出现了令人担忧的趋势。早期检测和积极管理对于预防和减轻微血管和大血管并发症以及死亡负担至关重要。获得新型疗法可改善以患者为中心的结局，而不仅仅是血糖控制。精准医学，包括多组学和药物基因组学，有望增进对疾病异质性的理解，从而实现靶向治疗。技术可能会改善结局，但其潜力尚未实现。尽管取得了进展，但改变这一流行趋势仍存在重大障碍。本次研讨会对2型糖尿病护理的最新进展进行了以临床为重点的综述，包括争议和未来方向。
